07:43 EST Harmony Biosciences (HRMY) backs FY26 revenue view $1B-$1.04B, consensus $1.01B
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences downgraded to Hold from Buy at Deutsche Bank
- Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Cheat Sheet
- Harmony Biosciences downgraded to Hold from Buy at Truist
- Harmony Biosciences price target raised to $50 from $46 at Mizuho
- Harmony Biosciences receives FDA approval for Wakix for pediatric cataplexy